TTR and amyloidosis: With the recent Food and Drug Administration (FDA) approval of drug therapy for hereditary transthyretin-mediated amyloidosis based on siRNA (FDA 2018), our findings open new perspectives for applying RNAi to diseases of the CNS and encourage the development of new noninvasive delivery methods targeting specific cell types.